Biopharmaceutical Regulations and Guidelines in India
Biopharmaceutical regulations in India provide a framework for ensuring the quality, safety and efficacy of biological medicinal products. Regulatory requirements vary according to the product, its stage of development and its intended use.
The Central Drugs Standard Control Organization (CDSCO), headed by the Drugs Controller General (India) [DCG(I)], has a central role in the regulation of new drugs, clinical trials and biological products in India.
Biopharmaceutical Regulations in India
Biopharmaceutical regulations in India are supported by the Drugs and Cosmetics Act and the rules made under it, which provide an important legal foundation for pharmaceutical regulation.
The New Drugs and Clinical Trials Rules (NDCTR), 2019 establish requirements relating to new drugs, investigational new drugs, clinical trials, bioavailability and bioequivalence studies and Ethics Committees.
Biological products that meet applicable definitions under the regulatory framework must comply with the corresponding requirements for development, clinical investigation and marketing authorisation.
CDSCO and Biopharmaceutical Regulation
CDSCO is India’s national regulatory authority for drugs and performs regulatory functions relating to new-drug development and approval.
Its responsibilities include reviewing applications for clinical trials and new drugs, evaluating submitted quality, nonclinical and clinical information, overseeing applicable regulatory processes and monitoring the safety of approved medicinal products.
Subject Expert Committees may also provide expert recommendations during the regulatory review of certain applications.
Current regulatory information and requirements are available through the Central Drugs Standard Control Organization (CDSCO).
Preclinical Development
Before clinical investigation, biopharmaceutical products undergo appropriate laboratory and nonclinical evaluation.
Preclinical development may include pharmacological, pharmacokinetic and toxicological studies, together with product-specific testing necessary to characterise biological activity and potential safety risks.
Applicable studies should follow relevant regulatory requirements and quality standards, including Good Laboratory Practice where required.
Clinical Trials
Clinical trials involving new drugs and investigational new drugs in India are regulated under the NDCTR 2019.
Sponsors must obtain the applicable regulatory permission before conducting regulated clinical trials and comply with requirements relating to study protocols, investigators, Ethics Committees, informed consent, safety reporting and trial documentation.
Applications and regulatory submissions are handled through processes established by CDSCO.
For additional background, see Indian Clinical Trial and Safety Regulations: From Schedule Y to NDCTR 2019.
Ethics Committees and Participant Protection
Ethics Committees have an important role in protecting the rights, safety and well-being of clinical-trial participants.
Ethics Committees involved in regulated clinical trials must meet applicable registration and regulatory requirements. Clinical research must also comply with requirements concerning informed consent and the reporting and management of serious adverse events.
Similar Biologics
India has established specific regulatory guidance for similar biologics. Development of a similar biologic requires a stepwise comparison with an appropriate reference biological product to establish similarity in quality, safety and efficacy.
The development programme may include comparative quality characterisation, nonclinical studies and clinical studies, with the extent of evidence determined by applicable regulatory requirements and scientific considerations.
India’s similar-biologics framework continues to evolve as scientific knowledge and international regulatory approaches develop.
Manufacturing and Quality
Biopharmaceutical manufacturing requires appropriate control of starting materials, manufacturing processes, facilities and product quality.
Manufacturers must comply with applicable Good Manufacturing Practice (GMP), quality-control and licensing requirements to help ensure that biological products are consistently produced according to established quality standards.
Post-Marketing Safety
Regulatory responsibilities continue after a biopharmaceutical product receives marketing authorisation.
Marketing authorisation holders must comply with applicable pharmacovigilance and post-marketing requirements, including collection and evaluation of safety information and submission of required safety reports.
The Indian regulatory framework therefore covers the biopharmaceutical lifecycle from preclinical development and clinical trials through regulatory review, manufacturing, marketing authorisation and continuing safety monitoring.
You may be interested in the programs below:
